Quick Answer
PRECIGEN, INC. reported Research And Development Expense of $41.33 million for the year ending 2025.
- PRECIGEN, INC. showed a decrease of -22.1% in Research And Development Expense from 2024 to 2025.
- This data is from PRECIGEN, INC.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2011 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2012: $14.36 million | Q1 2013: $11.41 million | Q2 2013: $13.51 million | Q3 2013: $10.67 million | Q1 2014: $12.06 million | Q2 2014: $14.43 million | Q3 2014: $14.85 million | Q1 2015: $79.31 million | Q2 2015: $20.38 million | Q3 2015: $21.60 million | Q1 2016: $25.86 million | Q2 2016: $28.38 million | Q3 2016: $29.04 million | Q1 2017: $34.18 million | Q2 2017: $34.01 million | Q3 2017: $36.47 million | Q1 2018: $37.27 million | Q2 2018: $42.05 million | Q3 2018: $44.89 million | Q1 2019: $33.06 million | Q2 2019: $34.52 million | Q3 2019: $31.48 million.
- Over the full 11 years of available data (2011 to 2025), PRECIGEN, INC.'s Research And Development Expense has declined by 41.1%.
- Historical annual values: Fiscal year 2025: $41.33 million | Fiscal year 2024: $53.07 million | Fiscal year 2023: $48.61 million | Fiscal year 2018: $404.59 million | Fiscal year 2017: $143.21 million | Fiscal year 2016: $112.14 million | Fiscal year 2015: $147.48 million | Fiscal year 2014: $58.98 million | Fiscal year 2013: $48.14 million | Fiscal year 2012: $64.03 million | Fiscal year 2011: $70.23 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: